Peptable

Acetyl tetrapeptide-5

is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation

Peptide

Alanine

Ala / A · hydrophobic residue · neutral charge

Amino acid

AOD-9604

is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials

Peptide

Arginine

Arg / R · basic residue · positive charge

Amino acid

Argireline

is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner

Peptide

Asparagine

Asn / N · polar residue · neutral charge

Amino acid

Aspartic acid

Asp / D · acidic residue · negative charge

Amino acid

BPC-157

is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects

Peptide

Comparison

BPC-157 vs FOXO4-DRI

Also see:

BPC-157FOXO4-DRI

Function

While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38.

Mechanism

While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, FOXO4-DRI is a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38.

Receptor

BPC-157

VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, with downstream eNOS and nitric-oxide–mediated signaling11

FOXO4-DRI

Intracellular target is the FOXO4–p53 protein–protein interaction interface; it does not signal via a traditional cell-surface receptor38

Organism or Origin

BPC-157

Synthetic peptide derived from a naturally occurring human gastric 'Body Protection Compound' isolated from human gastric juice111

FOXO4-DRI

Synthetic peptide based on human FOXO4 transcription factor3898

Gene

BPC-157

Not assigned in the current dataset.

FOXO4-DRI

FOXO4

Summary

BPC-157 and FOXO4-DRI are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: BPC-157 is more often discussed in the realm of Gastroenterology, Musculoskeletal health, and Dermatology and aesthetics, whereas FOXO4-DRI is more often associated with the realm of Aging and longevity. Their biological logic is quite different: BPC-157 is a signaling modulator, whereas FOXO4-DRI is a protein interaction inhibitor. BPC-157 has a more synthetic analog origin, while FOXO4-DRI is closer to synthetic design background and both are still best understood as being in Preclinical development. FOXO4-DRI incorporates retro-inverso isomerization features that are not part of BPC-157, while their sequence patterns also diverge, with BPC-157 showing proline-rich features and FOXO4-DRI showing protein-mimetic sequence features.